Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enact Holdings Inc (ACT) vs Becton Dickinson and Co (BDX) Price & Performance

Enact Holdings IncTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

Enact Holdings Inc vs Becton Dickinson and Co — how do they compare? Enact Holdings Inc trades at $49.07 (market cap $6.67B), while Becton Dickinson and Co trades at $181.29 (market cap $48.93B). The key difference: Becton Dickinson and Co is far larger — about 7.3× Enact Holdings Inc's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.

ACTBDX
Market Cap
$6.67B$48.93B
Sector
TechnologyHealth
52-Week High
$48.96$185.39
52-Week Low
$34.93$138.62
Enterprise Value
$6.96B$65.03B
Dividend Yield
1.98%2.34%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enact Holdings Inc

ACT trades at $48.96, up 0.6% today, near the consensus price target of $49.00. The stock shows strong fundamentals with a P/E of 10.23 and robust net income margin of 54.51%. Recent Q2 2026 earnings beat expectations at $1.26 per share. Technical indicators signal a bullish trend with moving averages supporting upside momentum. The company maintains consistent dividend payments and positive revenue growth projections.

Outlook remains positive with analyst consensus favoring buy/hold ratings and price targets suggesting limited upside. Key risks include execution challenges and market volatility. Earnings growth and dividend consistency provide support, but investors should monitor competitive pressures and macroeconomic factors that could impact performance.

Becton Dickinson and Co

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enact Holdings Inc

Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.

Read more on ACT

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX